Кишечной палочки производство белков

Кишечной палочки производство белков thumbnail

This article is about the biotechnological method. For the natural process in cells, see Gene expression.

Protein production is the biotechnological process of generating a specific protein. It is typically achieved by the manipulation of gene expression in an organism such that it expresses large amounts of a recombinant gene. This includes the transcription of the recombinant DNA to messenger RNA (mRNA), the translation of mRNA into polypeptide chains, which are ultimately folded into functional proteins and may be targeted to specific subcellular or extracellular locations.[1]

Protein production systems (in lab jargon also referred to as ‘expression systems’) are used in the life sciences, biotechnology, and medicine. Molecular biology research uses numerous proteins and enzymes, many of which are from expression systems; particularly DNA polymerase for PCR, reverse transcriptase for RNA analysis, restriction endonucleases for cloning, and to make proteins that are screened in drug discovery as biological targets or as potential drugs themselves. There are also significant applications for expression systems in industrial fermentation, notably the production of biopharmaceuticals such as human insulin to treat diabetes, and to manufacture enzymes.

Protein production systems[edit]

Commonly used protein production systems include those derived from bacteria,[2]yeast,[3][4]baculovirus/insect,[5]mammalian cells,[6][7] and more recently filamentous fungi such as Myceliophthora thermophila.[8] When biopharmaceuticals are produced with one of these systems, process-related impurities termed host cell proteins also arrive in the final product in trace amounts.[9]

Cell-based systems[edit]

The oldest and most widely used expression systems are cell-based and may be defined as the “combination of an expression vector, its cloned DNA, and the host for the vector that provide a context to allow foreign gene function in a host cell, that is, produce proteins at a high level“.[10][11] Overexpression is an abnormally and excessively high level of gene expression which produces a pronounced gene-related phenotype.[12][13]

There are many ways to introduce foreign DNA to a cell for expression, and many different host cells may be used for expression — each expression system has distinct advantages and liabilities. Expression systems are normally referred to by the host and the DNA source or the delivery mechanism for the genetic material. For example, common hosts are bacteria (such as E.coli, B. subtilis), yeast (such as S.cerevisiae[4]) or eukaryotic cell lines. Common DNA sources and delivery mechanisms are viruses (such as baculovirus, retrovirus, adenovirus), plasmids, artificial chromosomes and bacteriophage (such as lambda). The best expression system depends on the gene involved, for example the Saccharomyces cerevisiae is often preferred for proteins that require significant posttranslational modification. Insect or mammal cell lines are used when human-like splicing of mRNA is required. Nonetheless, bacterial expression has the advantage of easily producing large amounts of protein, which is required for X-ray crystallography or nuclear magnetic resonance experiments for structure determination.

Because bacteria are prokaryotes, they are not equipped with the full enzymatic machinery to accomplish the required post-translational modifications or molecular folding. Hence, multi-domain eukaryotic proteins expressed in bacteria often are non-functional. Also, many proteins become insoluble as inclusion bodies that are difficult to recover without harsh denaturants and subsequent cumbersome protein-refolding.

To address these concerns, expressions systems using multiple eukaryotic cells were developed for applications requiring the proteins be conformed as in, or closer to eukaryotic organisms: cells of plants (i.e. tobacco), of insects or mammalians (i.e. bovines) are transfected with genes and cultured in suspension and even as tissues or whole organisms, to produce fully folded proteins. Mammalian in vivo expression systems have however low yield and other limitations (time-consuming, toxicity to host cells,..). To combine the high yield/productivity and scalable protein features of bacteria and yeast, and advanced epigenetic features of plants, insects and mammalians systems, other protein production systems are developed using unicellular eukaryotes (i.e. non-pathogenic ‘Leishmania‘ cells).

Bacterial systems[edit]

Escherichia coli[edit]

E. coli, one of the most popular hosts for artificial gene expression.

E. coli is one of the most widely used expression hosts, and DNA is normally introduced in a plasmid expression vector. The techniques for overexpression in E. coli are well developed and work by increasing the number of copies of the gene or increasing the binding strength of the promoter region so assisting transcription.

For example, a DNA sequence for a protein of interest could be cloned or subcloned into a high copy-number plasmid containing the lac (often LacUV5) promoter, which is then transformed into the bacterium E. coli. Addition of IPTG (a lactose analog) activates the lac promoter and causes the bacteria to express the protein of interest.

E. coli strain BL21 and BL21(DE3) are two strains commonly used for protein production. As members of the B lineage, they lack lon and OmpT proteases, protecting the produced proteins from degradation. The DE3 prophage found in BL21(DE3) provides T7 RNA polymerase (driven by the LacUV5 promoter), allowing for vectors with the T7 promoter to be used instead.[14]

Corynebacterium[edit]

Non-pathogenic species of the gram-positive Corynebacterium are used for the commercial production of various amino acids. The C. glutamicum species is widely used for producing glutamate and lysine,[15] components of human food, animal feed and pharmaceutical products.

Expression of functionally active human epidermal growth factor has been done in C. glutamicum,[16] thus demonstrating a potential for industrial-scale production of human proteins. Expressed proteins can be targeted for secretion through either the general, secretory pathway (Sec) or the twin-arginine translocation pathway (Tat).[17]

Unlike gram-negative bacteria, the gram-positive Corynebacterium lack lipopolysaccharides that function as antigenic endotoxins in humans.

Pseudomonas fluorescens[edit]

The non-pathogenic and gram-negative bacteria, Pseudomonas fluorescens, is used for high level production of recombinant proteins; commonly for the development bio-therapeutics and vaccines. P. fluorescens is a metabolically versatile organism, allowing for high throughput screening and rapid development of complex proteins. P. fluorescens is most well known for its ability to rapid and successfully produce high titers of active, soluble protein.[18]

Eukaryotic systems[edit]

Yeasts[edit]

Expression systems using either S. cerevisiae or Pichia pastoris allow stable and lasting production of proteins that are processed similarly to mammalian cells, at high yield, in chemically defined media of proteins.

Filamentous fungi[edit]

Filamentous fungi, especially Aspergillus and Trichoderma, but also more recently Myceliophthora thermophila C1[8] have been developed into expression platforms for screening and production of diverse industrial enzymes. The expression system C1 shows a low viscosity morphology in submerged culture, enabling the use of complex growth and production media.

Baculovirus-infected cells[edit]

Baculovirus-infected insect cells[19] (Sf9, Sf21, High Five strains) or mammalian cells[20] (HeLa, HEK 293) allow production of glycosylated or membrane proteins that cannot be produced using fungal or bacterial systems.[19] It is useful for production of proteins in high quantity. Genes are not expressed continuously because infected host cells eventually lyse and die during each infection cycle.[21]

Non-lytic insect cell expression[edit]

Non-lytic insect cell expression is an alternative to the lytic baculovirus expression system. In non-lytic expression, vectors are transiently or stably transfected into the chromosomal DNA of insect cells for subsequent gene expression.[22][23] This is followed by selection and screening of recombinant clones.[24] The non-lytic system has been used to give higher protein yield and quicker expression of recombinant genes compared to baculovirus-infected cell expression.[23] Cell lines used for this system include: Sf9, Sf21 from Spodoptera frugiperda cells, Hi-5 from Trichoplusia ni cells, and Schneider 2 cells and Schneider 3 cells from Drosophila melanogaster cells.[22][24] With this system, cells do not lyse and several cultivation modes can be used.[22] Additionally, protein production runs are reproducible.[22][23] This system gives a homogeneous product.[23] A drawback of this system is the requirement of an additional screening step for selecting viable clones.[24]

Читайте также:  Патогенные кишечные палочки и вызываемые ими заболевания
Excavata[edit]

Leishmania tarentolae (cannot infect mammals) expression systems allow stable and lasting production of proteins at high yield, in chemically defined media. Produced proteins exhibit fully eukaryotic post-translational modifications, including glycosylation and disulfide bond formation.[citation needed]

Mammalian systems[edit]

The most common mammalian expression systems are Chinese Hamster ovary (CHO) and Human embryonic kidney (HEK) cells.[25][26][27]

  • Chinese hamster ovary cell[26]
  • Mouse myeloma lymphoblstoid (e.g. NS0 cell)[25]
  • Fully Human
    • Human embryonic kidney cells (HEK-293)[26]
    • Human embryonic retinal cells (Crucell’s Per.C6)[26]
    • Human amniocyte cells (Glycotope and CEVEC)

Cell-free systems[edit]

Cell-free production of proteins is performed in vitro using purified RNA polymerase, ribosomes, tRNA and ribonucleotides. These reagents may be produced by extraction from cells or from a cell-based expression system. Due to the low expression levels and high cost of cell-free systems, cell-based systems are more widely used.[28]

See also[edit]

  • Cellosaurus, a database of cell lines
  • Gene expression
  • Single-cell protein
  • Protein purification
  • Precision fermentation
  • Host cell protein
  • List of recombinant proteins

References[edit]

  1. ^ Gräslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gileadi O, et al. (February 2008). “Protein production and purification”. Nature Methods. 5 (2): 135–46. doi:10.1038/nmeth.f.202. PMC 3178102. PMID 18235434.
  2. ^ Baneyx F (October 1999). “Recombinant protein expression in Escherichia coli”. Current Opinion in Biotechnology. 10 (5): 411–21. doi:10.1016/s0958-1669(99)00003-8. PMID 10508629.
  3. ^ Cregg JM, Cereghino JL, Shi J, Higgins DR (September 2000). “Recombinant protein expression in Pichia pastoris”. Molecular Biotechnology. 16 (1): 23–52. doi:10.1385/MB:16:1:23. PMID 11098467. S2CID 35874864.
  4. ^ a b Malys N, Wishart JA, Oliver SG, McCarthy JE (2011). “Protein production in Saccharomyces cerevisiae for systems biology studies”. Methods in Systems Biology. Methods in Enzymology. 500. pp. 197–212. doi:10.1016/B978-0-12-385118-5.00011-6. ISBN 9780123851185. PMID 21943899.
  5. ^ Kost TA, Condreay JP, Jarvis DL (May 2005). “Baculovirus as versatile vectors for protein expression in insect and mammalian cells”. Nature Biotechnology. 23 (5): 567–75. doi:10.1038/nbt1095. PMC 3610534. PMID 15877075.
  6. ^ Rosser MP, Xia W, Hartsell S, McCaman M, Zhu Y, Wang S, Harvey S, Bringmann P, Cobb RR (April 2005). “Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression system”. Protein Expression and Purification. 40 (2): 237–43. doi:10.1016/j.pep.2004.07.015. PMID 15766864.
  7. ^ Lackner A, Genta K, Koppensteiner H, Herbacek I, Holzmann K, Spiegl-Kreinecker S, Berger W, Grusch M (September 2008). “A bicistronic baculovirus vector for transient and stable protein expression in mammalian cells”. Analytical Biochemistry. 380 (1): 146–8. doi:10.1016/j.ab.2008.05.020. PMID 18541133.
  8. ^ a b Visser H, Joosten V, Punt PJ, Gusakov AV, Olson PT, Joosten R, et al. (June 2011). “Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1”. Industrial Biotechnology. 7 (3): 214–223. doi:10.1089/ind.2011.7.214.
  9. ^ Wang, Xing; Hunter, Alan K.; Mozier, Ned M. (2009-06-15). “Host cell proteins in biologics development: Identification, quantitation and risk assessment”. Biotechnology and Bioengineering. 103 (3): 446–458. doi:10.1002/bit.22304. ISSN 0006-3592. PMID 19388135. S2CID 22707536.
  10. ^ “Definition: expression system”. Online Medical Dictionary. Centre for Cancer Education, University of Newcastle upon Tyne: Cancerweb. 1997-11-13. Retrieved 2008-06-10.
  11. ^ “Expression system – definition”. Biology Online. Biology-Online.org. 2005-10-03. Retrieved 2008-06-10.
  12. ^ “overexpression”. Oxford Living Dictionary. Oxford University Press. 2017. Retrieved 18 May 2017. The production of abnormally large amounts of a substance which is coded for by a particular gene or group of genes; the appearance in the phenotype to an abnormally high degree of a character or effect attributed to a particular gene.
  13. ^ “overexpress”. NCI Dictionary of Cancer Terms. National Cancer Institute at the National Institutes of Health. 2011-02-02. Retrieved 18 May 2017. overexpress
    In biology, to make too many copies of a protein or other substance. Overexpression of certain proteins or other substances may play a role in cancer development.
  14. ^ Jeong, H; Barbe, V; Lee, CH; Vallenet, D; Yu, DS; Choi, SH; Couloux, A; Lee, SW; Yoon, SH; Cattolico, L; Hur, CG; Park, HS; Ségurens, B; Kim, SC; Oh, TK; Lenski, RE; Studier, FW; Daegelen, P; Kim, JF (11 December 2009). “Genome sequences of Escherichia coli B strains REL606 and BL21(DE3)”. Journal of Molecular Biology. 394 (4): 644–52. doi:10.1016/j.jmb.2009.09.052. PMID 19786035.
  15. ^ Brinkrolf K, Schröder J, Pühler A, Tauch A (September 2010). “The transcriptional regulatory repertoire of Corynebacterium glutamicum: reconstruction of the network controlling pathways involved in lysine and glutamate production”. Journal of Biotechnology. 149 (3): 173–82. doi:10.1016/j.jbiotec.2009.12.004. PMID 19963020.
  16. ^ Date M, Itaya H, Matsui H, Kikuchi Y (January 2006). “Secretion of human epidermal growth factor by Corynebacterium glutamicum”. Letters in Applied Microbiology. 42 (1): 66–70. doi:10.1111/j.1472-765x.2005.01802.x. PMID 16411922.
  17. ^ Meissner D, Vollstedt A, van Dijl JM, Freudl R (September 2007). “Comparative analysis of twin-arginine (Tat)-dependent protein secretion of a heterologous model protein (GFP) in three different Gram-positive bacteria”. Applied Microbiology and Biotechnology. 76 (3): 633–42. doi:10.1007/s00253-007-0934-8. PMID 17453196. S2CID 6238466.
  18. ^ Retallack DM, Jin H, Chew L (February 2012). “Reliable protein production in a Pseudomonas fluorescens expression system”. Protein Expression and Purification. 81 (2): 157–65. doi:10.1016/j.pep.2011.09.010. PMID 21968453.
  19. ^ a b Altmann F, Staudacher E, Wilson IB, März L (February 1999). “Insect cells as hosts for the expression of recombinant glycoproteins”. Glycoconjugate Journal. 16 (2): 109–23. doi:10.1023/A:1026488408951. PMID 10612411. S2CID 34863069.
  20. ^ Kost TA, Condreay JP (October 1999). “Recombinant baculoviruses as expression vectors for insect and mammalian cells”. Current Opinion in Biotechnology. 10 (5): 428–33. doi:10.1016/S0958-1669(99)00005-1. PMID 10508635.
  21. ^ Yin J, Li G, Ren X, Herrler G (January 2007). “Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes”. Journal of Biotechnology. 127 (3): 335–47. doi:10.1016/j.jbiotec.2006.07.012. PMID 16959350.
  22. ^ a b c d Dyring, Charlotte (2011). “Optimising the drosophila S2 expression system for production of therapeutic vaccines”. BioProcessing Journal. 10 (2): 28–35. doi:10.12665/j102.dyring.
  23. ^ a b c d Olczak M, Olczak T (December 2006). “Comparison of different signal peptides for protein secretion in nonlytic insect cell system”. Analytical Biochemistry. 359 (1): 45–53. doi:10.1016/j.ab.2006.09.003. PMID 17046707.
  24. ^ a b c McCarroll L, King LA (October 1997). “Stable insect cell cultures for recombinant protein production”. Current Opinion in Biotechnology. 8 (5): 590–4. doi:10.1016/s0958-1669(97)80034-1. PMID 9353223.
  25. ^ a b Zhu J (2012-09-01). “Mammalian cell protein expression for biopharmaceutical production”. Biotechnology Advances. 30 (5): 1158–70. doi:10.1016/j.biotechadv.2011.08.022. PMID 21968146.
  26. ^ a b c d Almo SC, Love JD (June 2014). “Better and faster: improvements and optimization for mammalian recombinant protein production”. Current Opinion in Structural Biology. New constructs and expression of proteins / Sequences and topology. 26: 39–43. doi:10.1016/j.sbi.2014.03.006. PMC 4766836. PMID 24721463.
  27. ^ Hacker DL, Balasubramanian S (June 2016). “Recombinant protein production from stable mammalian cell lines and pools”. Current Opinion in Structural Biology. New constructs and expression of proteins • Sequences and topology. 38: 129–36. doi:10.1016/j.sbi.2016.06.005. PMID 27322762.
  28. ^ Rosenblum G, Cooperman BS (January 2014). “Engine out of the chassis: cell-free protein synthesis and its uses”. FEBS Letters. 588 (2): 261–8. doi:10.1016/j.febslet.2013.10.016. PMC 4133780. PMID 24161673.

Further reading[edit]

  • Higgins SJ, Hames BD (1999). Protein Expression: A Practical Approach. Oxford University Press. ISBN 978-0-19-963623-5.
  • Baneyx, François (2004). Protein Expression Technologies: Current Status and Future Trends. Garland Science. ISBN 978-0-9545232-5-1.
Читайте также:  Кишечная палочка в озере челябинск

External links[edit]

Источник

Escherichia coli (; commonly abbreviated E. coli) is a Gram-negative gammaproteobacterium commonly found in the lower intestine of warm-blooded organisms (endotherms). The descendants of two isolates, K-12 and B strain, are used routinely in molecular biology as both a tool and a model organism.

Diversity[edit]

Escherichia coli is one of the most diverse bacterial species, with several pathogenic strains with different symptoms and with only 20% of the genome common to all strains.[1] Furthermore, from the evolutionary point of view, the members of genus Shigella (dysenteriae, flexneri, boydii, sonnei) are actually E. coli strains “in disguise” (i.e. E. coli is paraphyletic to the genus).[2]

History[edit]

In 1885, Theodor Escherich, a German pediatrician, first discovered this species in the feces of healthy individuals and called it Bacterium coli commune because it is found in the colon and early classifications of Prokaryotes placed these in a handful of genera based on their shape and motility (at that time Ernst Haeckel’s classification of Bacteria in the kingdom Monera was in place[3]).[4]

Following a revision of Bacteria it was reclassified as Bacillus coli by Migula in 1895[5] and later reclassified as Escherichia coli.[6]

Due to its ease of culture and fast doubling, it was used in the early microbiology experiments; however, bacteria were considered primitive and pre-cellular and received little attention before 1944, when Avery, Macleod and McCarty demonstrated that DNA was the genetic material using Salmonella typhimurium, following which Escherichia coli was used for linkage mapping studies.[7]

Strains[edit]

Four of the many E. coli strains (K-12, B, C, and W) are thought of as model organism strains. These are classified in Risk Group 1 in biosafety guidelines.

Escherich’s isolate[edit]

The first isolate of Escherich was deposited in NCTC in 1920 by the Lister Institute in London (NCTC 86[1]).[8]

K-12[edit]

A strain was isolated from a stool sample of a patient convalescent from diphtheria and was labelled K-12 (not an antigen) in 1922 at Stanford University.[9] This isolate was used in 1940s by Charles E. Clifton to study nitrogen metabolism, who deposited it in ATCC (strain ATCC 10798) and lent it to Edward Tatum for his tryptophan biosynthesis experiments,[10] despite its idiosyncrasies due to the F+ λ+ phenotype.[7]
In the course of the passages it lost its O antigen[7] and in 1953 was cured first of its lambda phage (strain W1485 by UV by Joshua Lederberg and colleagues) and then in 1985 of the F plasmid by acridine orange curing.[citation needed] Strains derived from MG1655 include DH1, parent of DH5α and in turn of DH10B (rebranded as TOP10 by Invitrogen[11]).[12]
An alternative lineage from W1485 is that of W2637 (which contains an inversion rrnD-rrnE), which in turn resulted in W3110.[8]
Due to the lack of specific record-keeping, the “pedigree” of strains was not available and had to be inferred by consulting lab-book and records in order to set up the E. coli Genetic Stock Centre at Yale by Barbara Bachmann.[9] The different strains have been derived through treating E. coli K-12 with agents such as nitrogen mustard, ultra-violet radiation, X-ray etc. An extensive list of Escherichia coli K-12 strain derivatives and their individual construction, genotypes, phenotypes, plasmids and phage information can be viewed at Ecoliwiki.

B strain[edit]

A second common laboratory strain is the B strain, whose history is less straightforward and the first naming of the strain as E. coli B was by Delbrück and Luria in 1942 in their study of bacteriophages T1 and T7.[13] The original E. coli B strain, known then as Bacillus coli, originated from Félix d’Herelle from the Institut Pasteur in
Paris around 1918 who studied bacteriophages,[14] who claimed that it originated from Collection of the Institut Pasteur,[15] but no strains of that period exist.[8] The strain of d’Herelle was passed to Jules Bordet, Director of the Institut Pasteur du Brabant in Bruxelles[16] and his student André Gratia.[17] The former passed the strain to Ann Kuttner (“the Bact. coli obtained
from Dr. Bordet”)[18] and in turn to Eugène Wollman (B. coli Bordet),[19] whose son deposited it in 1963 (CIP 63.70) as “strain BAM” (B American), while André Gratia passed the strain to Martha Wollstein, a researcher at Rockefeller, who refers to the strain as “Brussels strain of Bacillus coli” in 1921,[20] who in turn passed it to Jacques Bronfenbrenner (B. coli P.C.), who passed it to Delbrück and Luria.[8][13]
This strain gave rise to several other strains, such as REL606 and BL21.[8]

C strain[edit]

E. coli C is morphologically distinct from other E. coli strains; it is more spherical in shape and has a distinct distribution of its nucleoid.[21]

W strain[edit]

The W strain was isolated from the soil near Rutgers University by Selman Waksman.[22]

Role in biotechnology[edit]

Because of its long history of laboratory culture and ease of manipulation, E. coli also plays an important role in modern biological engineering and industrial microbiology.[23] The work of Stanley Norman Cohen and Herbert Boyer in E. coli, using plasmids and restriction enzymes to create recombinant DNA, became a foundation of biotechnology.[24]

Considered a very versatile host for the production of heterologous proteins,[25] researchers can introduce genes into the microbes using plasmids, allowing for the mass production of proteins in industrial fermentation processes. Genetic systems have also been developed which allow the production of recombinant proteins using E. coli. One of the first useful applications of recombinant DNA technology was the manipulation of E. coli to produce human insulin.[26] Modified E. coli have been used in vaccine development, bioremediation, and production of immobilised enzymes.[25]

E. coli have been used successfully to produce proteins previously thought difficult or impossible in E. coli, such as those containing multiple disulfide bonds or those requiring post-translational modification for stability or function. The cellular environment of E. coli is normally too reducing for disulphide bonds to form, proteins with disulphide bonds therefore may be secreted to its periplasmic space, however, mutants in which the reduction of both thioredoxins and glutathione is impaired also allow disulphide bonded proteins to be produced in the cytoplasm of E. coli.[27] It has also been used to produce proteins with various post-translational modifications, including glycoproteins by using the N-linked glycosylation system of Campylobacter jejuni engineered into E. coli.[28][29] Efforts are currently under way to expand this technology to produce complex glycosylations.[30][31]

Studies are also being performed into programming E. coli to potentially solve complicated mathematics problems such as the Hamiltonian path problem.[32]

Model organism[edit]

E. coli is frequently used as a model organism in microbiology studies. Cultivated strains (e.g. E. coli K-12) are well-adapted to the laboratory environment, and, unlike wild type strains, have lost their ability to thrive in the intestine. Many lab strains lose their ability to form biofilms.[33][34] These features protect wild type strains from antibodies and other chemical attacks, but require a large expenditure of energy and material resources.

In 1946, Joshua Lederberg and Edward Tatum first described the phenomenon known as bacterial conjugation using E. coli as a model bacterium,[35] and it remains a primary model to study conjugation.[36]E. coli was an integral part of the first experiments to understand phage genetics,[37] and early researchers, such as Seymour Benzer, used E. coli and phage T4 to understand the topography of gene structure.[38] Prior to Benzer’s research, it was not known whether the gene was a linear structure, or if it had a branching pattern.

Читайте также:  От чего может появится кишечная палочка

E. coli was one of the first organisms to have its genome sequenced; the complete genome of E. coli K-12 was published by Science in 1997.[39]

Lenski’s long-term evolution experiment[edit]

The long-term evolution experiments using E. coli, begun by Richard Lenski in 1988, have allowed direct observation of major evolutionary shifts in the laboratory.[40] In this experiment, one population of E. coli unexpectedly evolved the ability to aerobically metabolize citrate. This capacity is extremely rare in E. coli. As the inability to grow aerobically is normally used as a diagnostic criterion with which to differentiate E. coli from other, closely related bacteria such as Salmonella, this innovation may mark a speciation event observed in the lab.

References[edit]

  1. ^ Lukjancenko, O.; Wassenaar, T.M.; Ussery, D.W. (2010). “Comparison of 61 sequenced Escherichia coli genomes”. Microb. Ecol. 60 (4): 708–720. doi:10.1007/s00248-010-9717-3. PMC 2974192. PMID 20623278.
  2. ^ Lan, R.; Reeves, P.R. (2002). “Escherichia coli in disguise: molecular origins of Shigella”. Microbes Infect. 4 (11): 1125–1132. doi:10.1016/S1286-4579(02)01637-4. PMID 12361912.
  3. ^ Haeckel, Ernst (1867). Generelle Morphologie der Organismen. Reimer, Berlin. ISBN 978-1-144-00186-3.
  4. ^ Escherich T (1885). “Die Darmbakterien des Neugeborenen und Säuglinge”. Fortschr. Med. 3: 515–522.
  5. ^ MIGULA (W.): Bacteriaceae (Stabchenbacterien). In: A. ENGLER and K. PRANTL (eds): Die Naturlichen Pfanzenfamilien, W. Engelmann, Leipzig, Teil I, Abteilung Ia, 1895, pp. 20–30.
  6. ^ CASTELLANI (A.) and CHALMERS (A.J.): Manual of Tropical Medicine, 3rd ed., Williams Wood and Co., New York, 1919.
  7. ^ a b c Lederber, J. 2004 E. coli K-12. Microbiology today 31:116
  8. ^ a b c d e Daegelen, P.; Studier, F. W.; Lenski, R. E.; Cure, S.; Kim, J. F. (2009). “Tracing Ancestors and Relatives of Escherichia coli B, and the Derivation of B Strains REL606 and BL21(DE3)”. Journal of Molecular Biology. 394 (4): 634–643. doi:10.1016/j.jmb.2009.09.022. PMID 19765591.
  9. ^ a b Bachmann, B. J. (1972). “Pedigrees of some mutant strains of Escherichia coli K-12”. Bacteriological Reviews. 36 (4): 525–557. doi:10.1128/mmbr.36.4.525-557.1972. PMC 408331. PMID 4568763.
  10. ^ Tatum E. L.; Lederberg J. (1947). “Gene recombination in the bacterium Escherichia coli”. J. Bacteriol. 53: 673–684. doi:10.1128/jb.53.6.673-684.1947.
  11. ^ E. coli genotypes – OpenWetWare
  12. ^ Meselson, M; Yuan, R (1968). “DNA restriction enzyme from E. Coli”. Nature. 217 (5134): 1110–4. Bibcode:1968Natur.217.1110M. doi:10.1038/2171110a0. PMID 4868368.
  13. ^ a b Delbrück M.; Luria S. E. (1942). “Interference between bacterial viruses: I. Interference between two bacterial viruses acting upon the same host, and the mechanism of virus growth”. Arch. Biochem. 1: 111–141.
  14. ^ D’Herelle F (1918). “Sur le rôle du microbe filtrant bactériophage dans la dysenterie bacillaire”. Comptes Rendus Acad. Sci. 167: 970–972.
  15. ^ d’Herelle, F. (1926). In Le bactériophage et son comportement. Monographies de l’Institut Pasteur, Masson et Cie, Libraires de l’Académie de Médecine, 120, Boulevard Saint Germain, Paris-VIe, France.
  16. ^ Bordet J.; Ciuca M. (1920). “Le bactériophage de d’Herelle, sa production et son interprétation”. Comptes Rendus Soc. Biol. 83: 1296–1298.
  17. ^ Gratia A.; Jaumain D. (1921). “Dualité du principe lytique du colibacille et du staphylococque”. Comptes Rendus Soc. Biol. 84: 882–884.
  18. ^ Kuttner A. G. (1923). “Bacteriophage phenomena”. J. Bacteriol. 8 (1): 49–101. doi:10.1128/jb.8.1.49-101.1923. PMC 379003. PMID 16558985.
  19. ^ Wollman E (1925). “Recherches sur la bactériophagie (phénomène de Twort-d’Hérelle)”. Ann. Inst. Pasteur. 39: 789–832.
  20. ^ Wollstein M (1921). “Studies on the phenomenon of d’Herelle with Bacillus dysenteriae”. J. Exp. Med. 34 (5): 467–476. doi:10.1084/jem.34.5.467. PMC 2128695. PMID 19868572.
  21. ^ Lieb, M.; Weigle, J. J.; Kellenberger, E. (1955). “A study of hybrids between two strains of Escherichia coli”. Journal of Bacteriology. 69 (4): 468–471. PMC 357561. PMID 14367303.
  22. ^ Colin T Archer; Jihyun F Kim; Haeyoung Jeong; Jin H Park; Claudia E Vickers; Sang Y Lee; Lars K Nielsen (2011). “The genome sequence of E. coli W (ATCC 9637): comparative genome analysis and an improved genome-scale reconstruction of E. coli”. BMC Genomics. 12: 9. doi:10.1186/1471-2164-12-9. PMC 3032704. PMID 21208457.
  23. ^ Lee SY (1996). “High cell-density culture of Escherichia coli”. Trends Biotechnol. 14 (3): 98–105. doi:10.1016/0167-7799(96)80930-9. PMID 8867291.
  24. ^ Russo E (January 2003). “The birth of biotechnology”. Nature. 421 (6921): 456–7. Bibcode:2003Natur.421..456R. doi:10.1038/nj6921-456a. PMID 12540923.
  25. ^ a b Cornelis P (2000). “Expressing genes in different Escherichia coli compartments”. Current Opinion in Biotechnology. 11 (5): 450–4. doi:10.1016/S0958-1669(00)00131-2. PMID 11024362.
  26. ^ Tof, Ilanit (1994). “Recombinant DNA Technology in the Synthesis of Human Insulin”. Little Tree Pty. Ltd. Retrieved 2007-11-30.
  27. ^ Paul H. Bessette; Fredrik Åslund; Jon Beckwith; George Georgiou (1999). “Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm”. Proc. Natl. Acad. Sci. U.S.A. 96 (24): 13703–8. Bibcode:1999PNAS…9613703B. doi:10.1073/pnas.96.24.13703. PMC 24128. PMID 10570136.
  28. ^ Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L (2010). “Production of glycoprotein vaccines in Escherichia coli”. Microbial Cell Factories. 9 (61): 494–7. doi:10.1186/1475-2859-9-61. PMC 2927510. PMID 20701771.
  29. ^ Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, Aebi M (2002). “N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli”. Science. 298 (5599): 1790–1793. Bibcode:2002Sci…298.1790W. doi:10.1126/science.298.5599.1790. PMID 12459590.
  30. ^ Valderrama-Rincon JD, Fisher AC, Merritt JH, Fan YY, Reading CA, Chhiba K, Heiss C, Azadi P, Aebi M, Delisa MP (2012). “An engineered eukaryotic protein glycosylation pathway in Escherichia coli”. Nat Chem Biol. 8 (5): 434–6. doi:10.1038/nchembio.921. PMC 3449280. PMID 22446837.
  31. ^ Huang CJ, Lin H, Yang X (2012). “Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements”. J Ind Microbiol Biotechnol. 39 (3): 383–99. doi:10.1007/s10295-011-1082-9. PMID 22252444.
  32. ^ “E. coli can solve math problems”. The Deccan Chronicle. July 26, 2009. Retrieved July 26, 2009.
  33. ^ Fux CA, Shirtliff M, Stoodley P, Costerton JW (2005). “Can laboratory reference strains mirror “real-world” pathogenesis?”. Trends Microbiol. 13 (2): 58–63. doi:10.1016/j.tim.2004.11.001. PMID 15680764.
  34. ^ Vidal O, Longin R, Prigent-Combaret C, Dorel C, Hooreman M, Lejeune P (1998). “Isolation of an Escherichia coli K-12 mutant strain able to form biofilms on inert surfaces: involvement of a new ompR allele that increases curli expression”. J. Bacteriol. 180 (9): 2442–9. doi:10.1128/JB.180.9.2442-2449.1998. PMC 107187. PMID 9573197.
  35. ^ Lederberg, Joshua; E.L. Tatum (October 19, 1946). “Gene recombination in E. coli” (PDF). Nature. 158 (4016): 558. Bibcode:1946Natur.158..558L. doi:10.1038/158558a0. PMID 21001945. Source: National Library of Medicine – The Joshua Lederberg Papers
  36. ^ F Xavier Gomis-Rüth; Miquel Coll (December 2006). “Cut and move: protein machinery for DNA processing in bacterial conjugation”. Current Opinion in Structural Biology. 16 (6): 744–752. doi:10.1016/j.sbi.2006.10.004. hdl:10261/104348. PMID 17079132.
  37. ^ “The Phage Course – Origins”. Cold Spring Harbor Laboratory. 2006. Archived from the original on September 16, 2006. Retrieved 2007-12-03.
  38. ^ Benzer, Seymour (March 1961). “On the topography of the genetic fine structure”. PNAS. 47 (3): 403–15. Bibcode:1961PNAS…47..403B. doi:10.1073/pnas.47.3.403. PMC 221592. PMID 16590840.
  39. ^ Frederick R. Blattner; Guy Plunkett III; Craig Bloch; Nicole Perna; Valerie Burland; Monica Riley; Julio Collado-Vides; Jeremy Glasner; Christopher Rode; George Mayhew; Jason Gregor; Nelson Davis; Heather Kirkpatrick; Michael Goeden; Debra Rose; Bob Mau; Ying Shao (September 5, 1997). “The complete genome sequence of Escherichia coli K-12”. Science. 277 (5331): 1453–1462. doi:10.1126/science.277.5331.1453. PMID 9278503.
  40. ^ Bob Holmes (June 9, 2008). “Bacteria make major evolutionary shift in the lab”. New Scientist. Archived from the original on August 28, 2008.

Источник